Morgan Stanley Anavex Life Sciences Corp. Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Morgan Stanley holds 627,207 shares of AVXL stock, worth $5.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

627,207

Previous 864,728 27.47%

Holding current value

$5.7 Million

Previous $7.42 Million 22.06%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2025 Aug 15, 2025	SELL	$7.37 - $9.63 $1.75 Million - $2.29 Million	-237,521 Reduced 27.47%	627,207 $5.78 Million
Q1 2025 May 15, 2025	SELL	$7.85 - $13.46 $309,533 - $530,741	-39,431 Reduced 4.36%	864,728 $7.42 Million
Q4 2024 Feb 14, 2025	BUY	$5.11 - $12.56 $948,436 - $2.33 Million	185,604 Added 25.83%	904,159 $9.71 Million
Q3 2024 May 14, 2025	BUY	$4.11 - $7.04 $1.15 Million - $1.98 Million	280,715 Added 64.11%	718,555 $4.08 Million
Q3 2024 Nov 14, 2024	BUY	$4.11 - $7.04 $1.15 Million - $1.98 Million	280,715 Added 64.11%	718,555 $4.08 Million
Q2 2024 May 14, 2025	SELL	$3.39 - $5.02 $1.58 Million - $2.34 Million	-466,319 Reduced 51.57%	437,840 $1.85 Million
Q2 2024 Oct 17, 2024	BUY	$3.39 - $5.02 $329,541 - $487,994	97,210 Added 28.54%	437,840 $1.85 Million
Q2 2024 Aug 14, 2024	BUY	$3.39 - $5.02 $329,541 - $487,994	97,210 Added 28.54%	437,840 $1.85 Million
Q1 2024 Oct 17, 2024	SELL	$4.55 - $6.75 $442,305 - $656,167	-97,210 Reduced 22.2%	340,630 $1.73 Million
Q1 2024 Aug 16, 2024	SELL	$4.55 - $6.75 $507,657 - $753,117	-111,573 Reduced 24.67%	340,630 $1.73 Million
Q1 2024 May 15, 2024	SELL	$4.55 - $6.75 $507,657 - $753,117	-111,573 Reduced 24.67%	340,630 $1.73 Million
Q4 2023 Aug 16, 2024	BUY	$5.04 - $9.95 $72,389 - $142,911	14,363 Added 3.28%	452,203 $4.21 Million
Q4 2023 Feb 13, 2024	BUY	$5.04 - $9.95 $906,998 - $1.79 Million	179,960 Added 66.1%	452,203 $4.21 Million
Q3 2023 Nov 15, 2023	SELL	$6.55 - $9.37 $1,120 - $1,602	-171 Reduced 0.06%	272,243 $1.78 Million
Q2 2023 Aug 14, 2023	BUY	$7.66 - $9.5 $83,708 - $103,816	10,928 Added 4.18%	272,414 $2.21 Million
Q1 2023 May 15, 2023	SELL	$8.32 - $11.75 $1.02 Million - $1.43 Million	-121,997 Reduced 31.81%	261,486 $2.24 Million
Q4 2022 Feb 14, 2023	BUY	$7.65 - $14.43 $1.26 Million - $2.39 Million	165,312 Added 75.77%	383,483 $3.55 Million
Q3 2022 Nov 14, 2022	SELL	$8.9 - $12.86 $5.58 Million - $8.06 Million	-626,644 Reduced 74.18%	218,171 $2.25 Million
Q2 2022 Oct 27, 2022	BUY	$7.31 - $12.84 $725,210 - $1.27 Million	99,208 Added 13.31%	844,815 $8.46 Million
Q2 2022 Aug 15, 2022	BUY	$7.31 - $12.84 $725,210 - $1.27 Million	99,208 Added 13.31%	844,815 $8.46 Million
Q1 2022 Oct 27, 2022	SELL	$9.74 - $17.69 $966,285 - $1.75 Million	-99,208 Reduced 11.74%	745,607 $9.18 Million
Q1 2022 May 13, 2022	BUY	$9.74 - $17.69 $3.78 Million - $6.87 Million	388,392 Added 108.73%	745,607 $9.18 Million
Q4 2021 Feb 14, 2022	BUY	$16.88 - $23.31 $1.82 Million - $2.51 Million	107,828 Added 43.24%	357,215 $6.2 Million
Q3 2021 Nov 15, 2021	BUY	$16.82 - $25.75 $4.19 Million - $6.42 Million	249,387 New	249,387 $4.48 Million

Others Institutions Holding AVXL

# of Institutions

196

Shares Held

31.9M

Call Options Held

1.16M

Put Options Held

804K

View Full List

About ANAVEX LIFE SCIENCES CORP.

Ticker AVXL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,942,800
Market Cap $709M
Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...

More about AVXL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account